GAY, Francesca Maria
 Distribuzione geografica
Continente #
NA - Nord America 4.077
EU - Europa 1.981
AS - Asia 1.301
OC - Oceania 72
AF - Africa 58
SA - Sud America 55
Totale 7.544
Nazione #
US - Stati Uniti d'America 3.962
IT - Italia 685
CN - Cina 536
DE - Germania 288
GB - Regno Unito 229
JP - Giappone 210
FR - Francia 160
IN - India 139
VN - Vietnam 116
CA - Canada 100
ES - Italia 85
RU - Federazione Russa 69
KR - Corea 68
AU - Australia 65
PL - Polonia 61
CZ - Repubblica Ceca 56
NL - Olanda 48
HK - Hong Kong 42
SE - Svezia 32
CH - Svizzera 31
IE - Irlanda 31
ZA - Sudafrica 31
SA - Arabia Saudita 30
AT - Austria 29
SG - Singapore 27
TW - Taiwan 23
BE - Belgio 22
PT - Portogallo 22
UA - Ucraina 19
CO - Colombia 18
FI - Finlandia 17
HU - Ungheria 16
PH - Filippine 16
DK - Danimarca 15
TR - Turchia 15
GR - Grecia 14
CL - Cile 12
MX - Messico 12
MY - Malesia 12
RO - Romania 12
AR - Argentina 10
BR - Brasile 10
ID - Indonesia 10
IL - Israele 10
NO - Norvegia 10
IR - Iran 9
LT - Lituania 9
TH - Thailandia 9
NZ - Nuova Zelanda 7
DZ - Algeria 6
IQ - Iraq 6
AM - Armenia 5
MA - Marocco 5
TN - Tunisia 5
AE - Emirati Arabi Uniti 4
LU - Lussemburgo 4
NG - Nigeria 4
RS - Serbia 4
JO - Giordania 3
LB - Libano 3
MK - Macedonia 3
PE - Perù 3
AL - Albania 2
CY - Cipro 2
EG - Egitto 2
HR - Croazia 2
IS - Islanda 2
NP - Nepal 2
PK - Pakistan 2
SC - Seychelles 2
TJ - Tagikistan 2
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
ET - Etiopia 1
GH - Ghana 1
MD - Moldavia 1
MG - Madagascar 1
PA - Panama 1
SI - Slovenia 1
SV - El Salvador 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
VE - Venezuela 1
Totale 7.544
Città #
Fairfield 405
Houston 291
Ashburn 250
Santa Cruz 246
Seattle 234
Woodbridge 234
Cambridge 228
Buffalo 198
Ann Arbor 154
Torino 134
Wilmington 122
Turin 102
Dong Ket 89
Beijing 85
Fleming Island 60
San Diego 56
Shanghai 52
Chicago 49
Tokyo 46
Milan 41
Warsaw 40
Ottawa 39
Pisa 36
Guangzhou 33
London 32
Los Angeles 32
Nanjing 28
Vienna 28
Clearwater 27
Dublin 27
Mountain View 27
Muizenberg 27
Bengaluru 26
Boardman 26
New York 26
University Park 26
Hangzhou 25
Las Vegas 25
Norwalk 25
Wuhan 24
Toronto 22
Chennai 21
Duncan 21
Riyadh 20
Stockholm 19
Dallas 18
Provo 18
Rochester 18
Taipei 18
Changsha 16
Fuzhou 16
Madrid 16
Phoenix 16
Brooklyn 15
Madison 15
Sydney 15
Budapest 14
Loma Linda 14
San Francisco 14
Xian 14
Barcelona 13
Helsinki 13
Lake Forest 13
Seoul 13
Pinerolo 12
Central District 11
Des Moines 11
Bologna 10
Central 10
Chengdu 10
Council Bluffs 10
Denver 10
Hamburg 10
Henderson 10
Mumbai 10
Rome 10
San Jose 10
Berlin 9
Bordentown 9
Brookline 9
Buenos Aires 9
Chiyoda-ku 9
Hebei 9
Moscow 9
Osaka 9
Raritan 9
Singapore 9
Bari 8
Bogotá 8
Changchun 8
Clayton 8
Cleveland 8
Collegeville 8
Jakarta 8
Nürnberg 8
Paris 8
Riva 8
Ichibacho 7
Jinan 7
Leawood 7
Totale 4.372
Nome #
Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors, file e27ce42c-b4b4-2581-e053-d805fe0acbaa 660
Management of older patients with multiple myeloma, file e27ce426-d3d7-2581-e053-d805fe0acbaa 327
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients., file e27ce426-d3d5-2581-e053-d805fe0acbaa 282
The role of pre-transplant induction regimens and autologous stem cell transplantation in the era of novel targeted agents, file e27ce427-812e-2581-e053-d805fe0acbaa 279
Nuances in the Management of Older People With Multiple Myeloma, file e27ce42a-e59d-2581-e053-d805fe0acbaa 249
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma, file e27ce435-5f64-2581-e053-d805fe0acbaa 245
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project, file e27ce435-7fed-2581-e053-d805fe0acbaa 229
A Simple Score, Based On Geriatric Assessment, Improves Prediction of Survival, and Risk Of Serious Adverse Events In Elderly Newly Diagnosed Multiple Myeloma Patients, file e27ce42a-ee98-2581-e053-d805fe0acbaa 222
Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma, file e27ce430-af99-2581-e053-d805fe0acbaa 213
Trichoderma species fungemia after high-dose chemotherapy and autologous stem cell transplantation: a case report, file e27ce428-b44a-2581-e053-d805fe0acbaa 194
Autologous Transplantation and Maintenance Therapy in Multiple Myeloma, file e27ce432-dc72-2581-e053-d805fe0acbaa 191
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results, file e27ce427-86ab-2581-e053-d805fe0acbaa 190
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial, file e27ce435-9730-2581-e053-d805fe0acbaa 180
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group, file e27ce42f-8b46-2581-e053-d805fe0acbaa 170
Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: A meta-analysis, file e27ce42f-8645-2581-e053-d805fe0acbaa 163
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: Results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study, file e27ce427-7c64-2581-e053-d805fe0acbaa 160
Therapeutic monoclonal antibodies and antibody products: Current practices and development in multiple myeloma, file e27ce42f-7537-2581-e053-d805fe0acbaa 156
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma, file e27ce426-f782-2581-e053-d805fe0acbaa 153
Management of myeloma: an Italian perspective, file e27ce426-ce62-2581-e053-d805fe0acbaa 125
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials, file e27ce430-fb2b-2581-e053-d805fe0acbaa 122
Emerging drugs and combinations to treat multiple myeloma, file e27ce430-f3b6-2581-e053-d805fe0acbaa 120
Lenalidomide maintenance with or without prednisone in newly diagnosed myeloma patients: A pooled analysis, file e27ce430-5f1c-2581-e053-d805fe0acbaa 110
High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib., file e27ce427-8454-2581-e053-d805fe0acbaa 108
From transplant to novel cellular therapies in multiple myeloma: EMN guidelines and future perspectives, file e27ce42c-54ed-2581-e053-d805fe0acbaa 100
Promises and pitfalls in the use of PD-1/PD-L1 inhibitors in multiple myeloma, file e27ce42f-55dd-2581-e053-d805fe0acbaa 100
Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents, file e27ce430-bd95-2581-e053-d805fe0acbaa 100
Autologous Transplantation in Elderly Multiple Myeloma Patients: Is the Procedure Cost Effective?, file e27ce427-822a-2581-e053-d805fe0acbaa 99
Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA), file e27ce42d-5d05-2581-e053-d805fe0acbaa 99
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis, file e27ce42f-6e99-2581-e053-d805fe0acbaa 97
European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications, file e27ce427-76e7-2581-e053-d805fe0acbaa 96
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network, file e27ce431-3459-2581-e053-d805fe0acbaa 96
Pursuing a curative approach in multiple myeloma: A review of new therapeutic strategies, file e27ce42f-55d7-2581-e053-d805fe0acbaa 90
Prevention and management of adverse events of novel agents in multiple myeloma: A consensus of the European Myeloma Network, file e27ce42f-6e94-2581-e053-d805fe0acbaa 90
European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when, file e27ce431-0632-2581-e053-d805fe0acbaa 88
Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate?, file e27ce42f-55d3-2581-e053-d805fe0acbaa 87
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN), file e27ce435-99a2-2581-e053-d805fe0acbaa 83
Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR, file e27ce430-fe9c-2581-e053-d805fe0acbaa 81
Autologous transplant for myeloma: When the old meets the new, file e27ce42f-90b7-2581-e053-d805fe0acbaa 80
Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs, file e27ce42f-65c2-2581-e053-d805fe0acbaa 79
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial, file e27ce431-d84e-2581-e053-d805fe0acbaa 72
Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma, file e27ce430-925f-2581-e053-d805fe0acbaa 70
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project, file e27ce435-990a-2581-e053-d805fe0acbaa 68
Cardiovascular organ damage and blood pressure levels predict adverse events in multiple myeloma patients undergoing carfilzomib therapy, file e27ce42f-a12e-2581-e053-d805fe0acbaa 60
Stem Cell Transplantation in Multiple Myeloma, file e27ce42f-5d6d-2581-e053-d805fe0acbaa 59
MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients, file e27ce426-f87f-2581-e053-d805fe0acbaa 57
Editorial: Exploiting the Immune System to Treat Multiple Myeloma: From Transplantation to Novel Treatment Approaches, file e27ce431-0571-2581-e053-d805fe0acbaa 57
Multiple myeloma patients undergoing carfilzomib: Development and validation of a risk score for cardiovascular adverse events prediction, file e27ce431-dbd0-2581-e053-d805fe0acbaa 52
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: A pooled analysis, file e27ce433-b2d9-2581-e053-d805fe0acbaa 51
Clinical and pharmacologic features of monoclonal antibodies and checkpoint blockade therapy in multiple myeloma, file 185097a3-5f0f-4eca-ba69-26ed618f2ebd 49
Chromosome 1 abnormalities in newly diagnosed elderly multiple myeloma patients treated with novel therapies., file e27ce426-f477-2581-e053-d805fe0acbaa 48
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma, file e27ce434-fc96-2581-e053-d805fe0acbaa 47
Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma, file e27ce431-52f2-2581-e053-d805fe0acbaa 46
Checkpoint inhibitors and myeloma: promises, deadlocks and new directions, file e27ce431-0ffc-2581-e053-d805fe0acbaa 45
CyTOF®: A New Tool to Decipher the Immunomodulatory Activity of Daratumumab, file e27ce42e-b74f-2581-e053-d805fe0acbaa 41
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde, file e27ce432-a6ac-2581-e053-d805fe0acbaa 37
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration, file e27ce435-4d46-2581-e053-d805fe0acbaa 37
Treatment of newly diagnosed elderly multiple myeloma, file e27ce435-7ca7-2581-e053-d805fe0acbaa 37
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension, file a80eb078-016b-45f2-b47c-8f0139cbeb1c 34
MRD Assessment in Multiple Myeloma: Progress and Challenges, file e27ce435-4a3c-2581-e053-d805fe0acbaa 34
Plasma cell leukemia: update on biology and therapy, file e27ce435-9d30-2581-e053-d805fe0acbaa 34
Effects of Carfilzomib Therapy on Left Ventricular Function in Multiple Myeloma Patients, file e27ce431-df1e-2581-e053-d805fe0acbaa 30
Anti-CD38 monoclonal antibodies in multiple myeloma: another cook in the kitchen?, file e27ce435-8d49-2581-e053-d805fe0acbaa 23
European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications, file e27ce432-5582-2581-e053-d805fe0acbaa 22
Moving Toward Continuous Therapy in Multiple Myeloma, file e27ce434-deab-2581-e053-d805fe0acbaa 21
Novel investigational drugs active as single agents in multiple myeloma, file e27ce435-a456-2581-e053-d805fe0acbaa 19
Special problems in the management of elderly patients with multiple myeloma, file e27ce435-8ee9-2581-e053-d805fe0acbaa 18
Redefining the treatment paradigm for multiple myeloma, file e27ce435-985b-2581-e053-d805fe0acbaa 16
Normalization of the Immunological Microenvironment and Sustained Minimal Residual Disease Negativity: Do We Need Both for Long-Term Control of Multiple Myeloma?, file 6e5a9826-b309-4ba1-b726-579d798b45ad 15
From transplant to novel cellular therapies in multiple myeloma: EMN guidelines and future perspectives, file e27ce42f-74db-2581-e053-d805fe0acbaa 14
Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing, file e27ce435-6515-2581-e053-d805fe0acbaa 14
Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials, file e27ce435-88a9-2581-e053-d805fe0acbaa 14
Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing, file a4e97a93-3d82-4aaa-b92d-85fef843542e 12
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials, file e27ce435-4971-2581-e053-d805fe0acbaa 12
European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications, file e27ce428-a199-2581-e053-d805fe0acbaa 11
Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma, file e27ce435-8204-2581-e053-d805fe0acbaa 11
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis, file c232163f-5136-48e3-926e-a6f057e605e6 10
Clinical and pharmacologic features of monoclonal antibodies and checkpoint blockade therapy in multiple myeloma, file e27ce435-4081-2581-e053-d805fe0acbaa 10
Antibody-drug conjugates: when chemotherapy meets immuno-oncology, file e27ce435-7fcc-2581-e053-d805fe0acbaa 9
CyTOF®: A New Tool to Decipher the Immunomodulatory Activity of Daratumumab, file e27ce435-8fab-2581-e053-d805fe0acbaa 9
CD38 as an immunotherapeutic target in multiple myeloma, file e27ce435-a5c4-2581-e053-d805fe0acbaa 9
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis, file e27ce435-866b-2581-e053-d805fe0acbaa 8
Multiple myeloma with t(11;14): unique biology and evolving landscape, file 55ead21a-32e1-46f1-be01-56413a9b4d6e 7
Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing, file e27ce431-1142-2581-e053-d805fe0acbaa 7
Novel investigational drugs active as single agents in multiple myeloma, file e27ce431-2880-2581-e053-d805fe0acbaa 7
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials, file e27ce42f-5419-2581-e053-d805fe0acbaa 6
CD38 as an immunotherapeutic target in multiple myeloma, file e27ce42f-83d9-2581-e053-d805fe0acbaa 6
Plasma cell leukemia: update on biology and therapy, file e27ce431-f436-2581-e053-d805fe0acbaa 6
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing, file ab42bacd-9a56-40a8-a10a-b605c8f38e7e 5
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: A pooled analysis, file e27ce42f-a041-2581-e053-d805fe0acbaa 5
The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma, file e27ce431-dbd1-2581-e053-d805fe0acbaa 5
Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options, file e27ce432-0f4b-2581-e053-d805fe0acbaa 5
Clinical and pharmacologic features of monoclonal antibodies and checkpoint blockade therapy in multiple myeloma, file e27ce432-2dad-2581-e053-d805fe0acbaa 5
Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients, file e27ce435-4549-2581-e053-d805fe0acbaa 5
Treatment of newly diagnosed elderly multiple myeloma, file e27ce435-7b03-2581-e053-d805fe0acbaa 5
Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma, file 46ef473b-1772-4ecc-a7cd-5c487348f742 4
MRD Assessment in Multiple Myeloma: Progress and Challenges, file e27ce431-ec0c-2581-e053-d805fe0acbaa 4
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial, file 64fe7309-43af-4f49-aab3-bcfc7e8ba23f 3
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma, file 80dfff5e-cb36-4f94-a39f-23ec8780c2cd 3
European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias, file e27ce42f-6ea3-2581-e053-d805fe0acbaa 3
Melphalan and its role in the management of patients with multiple myeloma, file e27ce431-e0d0-2581-e053-d805fe0acbaa 3
Totale 7.749
Categoria #
all - tutte 11.498
article - articoli 0
book - libri 0
conference - conferenze 278
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.776


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019288 0 0 0 0 0 0 0 0 34 58 132 64
2019/20201.016 66 81 65 124 78 72 56 91 145 82 80 76
2020/20211.738 70 132 107 123 130 186 131 252 139 140 121 207
2021/20222.022 199 110 123 232 175 80 226 140 93 104 316 224
2022/20231.845 97 114 301 236 142 137 234 152 159 136 111 26
2023/2024431 58 64 52 36 47 30 67 61 16 0 0 0
Totale 7.818